Alphabet precision health technology company Verily and OneOncology have announced a strategic collaboration for clinical trials.

Under the partnership, community OneOncology Research Network sites will get access to new tools for expediting trials and improving their cancer care delivery.

Verily's clinical trial management software (CTMS) platform SignalPath will be integrated across practices in OneR, the OneOncology Research Network, as part of the agreement.

Leveraging the SignalPath platform, trial sites will be able to improve their systems infrastructure and collaboration with sponsors, as well as streamline regulatory processes.

Using next-generation protocol digitisation technology, SignalPath will configure and systematise study protocol workflows and save time and effort of the site staff.

It helps improve the complexities, costs and time associated with running clinical trials and optimises for quality and time with participants.

OneOncology chief medical officer Dr Davey Daniel said: “Clinical trial research is core to high-quality cancer care programmes.

“By using technology to create a platform offering from OneR, we can help enhance our partners’ clinical trial programmes, which ultimately better democratises clinical trials, and improves health equity.”

The partnership between Verily and OneOncology aims to expand research opportunities across community oncology centres and will provide the potential to increase trial access and participation in new cancer therapies.

OneOncology plans to further develop connected solutions across its research and care product offerings and will continue to collaborate with Verily.

In September 2021, Verily concluded the acquisition of SignalPath, boosting its clinical research capabilities.